Zynex, Inc. (NASDAQ:ZYXI) Shares Purchased by JPMorgan Chase & Co.

JPMorgan Chase & Co. grew its holdings in shares of Zynex, Inc. (NASDAQ:ZYXI) by 3.3% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 40,985 shares of the company’s stock after acquiring an additional 1,318 shares during the period. JPMorgan Chase & Co. owned about 0.13% of Zynex worth $334,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Renaissance Technologies LLC raised its holdings in Zynex by 68.7% in the second quarter. Renaissance Technologies LLC now owns 189,762 shares of the company’s stock valued at $1,769,000 after acquiring an additional 77,300 shares in the last quarter. Millennium Management LLC raised its stake in shares of Zynex by 66.5% in the 2nd quarter. Millennium Management LLC now owns 297,082 shares of the company’s stock valued at $2,769,000 after purchasing an additional 118,615 shares in the last quarter. Barclays PLC raised its stake in shares of Zynex by 43.3% in the 3rd quarter. Barclays PLC now owns 28,821 shares of the company’s stock valued at $236,000 after purchasing an additional 8,713 shares in the last quarter. Jane Street Group LLC lifted its position in shares of Zynex by 8.9% during the third quarter. Jane Street Group LLC now owns 23,530 shares of the company’s stock worth $192,000 after purchasing an additional 1,929 shares during the last quarter. Finally, American Century Companies Inc. grew its stake in Zynex by 10.1% in the second quarter. American Century Companies Inc. now owns 31,159 shares of the company’s stock worth $290,000 after purchasing an additional 2,864 shares in the last quarter. 29.68% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have issued reports on ZYXI. HC Wainwright restated a “buy” rating and set a $17.00 price objective on shares of Zynex in a research note on Friday, December 6th. Royal Bank of Canada dropped their price target on Zynex from $12.00 to $11.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th.

Zynex Trading Down 2.3 %

NASDAQ ZYXI opened at $8.08 on Friday. The company has a debt-to-equity ratio of 1.66, a quick ratio of 3.15 and a current ratio of 3.94. Zynex, Inc. has a one year low of $7.15 and a one year high of $13.77. The company has a 50-day simple moving average of $8.12 and a 200-day simple moving average of $8.24. The firm has a market capitalization of $257.35 million, a PE ratio of 53.87 and a beta of 0.53.

Insider Buying and Selling at Zynex

In other Zynex news, CFO Daniel J. Moorhead sold 10,000 shares of the stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $7.88, for a total value of $78,800.00. Following the sale, the chief financial officer now directly owns 26,299 shares of the company’s stock, valued at $207,236.12. This trade represents a 27.55 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders sold a total of 30,000 shares of company stock worth $247,040 over the last ninety days. Company insiders own 52.13% of the company’s stock.

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.